Legal & General Group Plc Trims Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Legal & General Group Plc lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 13.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 828,917 shares of the biopharmaceutical company’s stock after selling 132,042 shares during the quarter. Legal & General Group Plc’s holdings in Alnylam Pharmaceuticals were worth $195,052,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ALNY. Allworth Financial LP boosted its holdings in shares of Alnylam Pharmaceuticals by 6.8% in the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 38 shares in the last quarter. Nixon Peabody Trust Co. raised its position in Alnylam Pharmaceuticals by 1.9% during the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after buying an additional 43 shares during the last quarter. IFP Advisors Inc increased its holdings in shares of Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 47 shares in the last quarter. Nwam LLC increased its holdings in shares of Alnylam Pharmaceuticals by 5.8% during the 4th quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 50 shares in the last quarter. Finally, National Bank of Canada FI increased its holdings in shares of Alnylam Pharmaceuticals by 9.0% during the 4th quarter. National Bank of Canada FI now owns 668 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 55 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $243.27 on Thursday. The stock has a market cap of $31.65 billion, a P/E ratio of -112.11 and a beta of 0.30. The firm has a 50 day simple moving average of $254.83 and a 200 day simple moving average of $258.93. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ALNY has been the topic of a number of research analyst reports. Stifel Nicolaus lifted their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a “buy” rating in a research note on Monday, March 31st. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $280.00 to $328.00 in a research note on Monday, March 24th. Needham & Company LLC reissued a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday. Redburn Atlantic started coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, March 31st. They issued a “buy” rating and a $353.00 price target for the company. Finally, Royal Bank of Canada upped their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a report on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have issued a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $316.25.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 1,213 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the transaction, the chief executive officer now owns 81,526 shares in the company, valued at $20,802,989.42. This represents a 1.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the transaction, the executive vice president now owns 14,321 shares in the company, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,234 shares of company stock worth $19,958,097 over the last 90 days. Corporate insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.